Biocryst Pharmaceuticals Inc(BCRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.5 | Insider Own | 14.12% | Shs Outstand | 255.3M | Perf Week | -18.49% |
| Market Cap | 2.12B | Forward P/E | 14.32 | EPS next Y | 125.05% | Insider Trans | -0.75% | Shs Float | 219.5M | Perf Month | -19.83% |
| Enterprise Value | 2.60B | PEG | - | EPS next Q | 0.09 | Inst Own | 90.19% | Short Float | 15.01% | Perf Quarter | 1.22% |
| Income | -0.38B | P/S | 2.25 | EPS this Y | -290.94% | Inst Trans | 4.83% | Short Ratio | 7.56 | Perf Half Y | -2.36% |
| Sales | 0.94B | P/B | - | EPS next 5Y | -16.36% | ROA | -75.79% | Short Interest | 32.94M | Perf YTD | 6.28% |
| Book/sh | -1.78 | P/C | 6 | EPS past 3/5Y | - | ROE | - | 52W High | -26.11% ($11.22) | Perf Year | 3.5% |
| Cash/sh | 1.38 | P/FCF | 5.95 | Sales past 3/5Y | 47.82% 117.89% | ROIC | -114.64% | 52W Low | 38.17% ($6.00) | Perf 3Y | 17.09% |
| Dividend Est. | - | EV/EBITDA | 6.73 | EPS Y/Y TTM | -737.08% | Gross Margin | 97.53% | Volatility(W/M) | 3.76% 4.08% | Perf 5Y | -45.46% |
| Dividend TTM | - | EV/Sales | 2.77 | Sales Y/Y TTM | 68.72% | Oper. Margin | 40.89% | ATR (14) | 0.45 | Perf 10Y | 91.45% |
| Dividend Ex-Date | - | Quick Ratio | 2.29 | EPS Q/Q | 1180.09% | Profit Margin | -40.9% | RSI (14) | 31.3 | Recom | 1.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.32 | Sales Q/Q | 33.61% | SMA20 | -14.32% ($9.68) | Beta | 0.54 | Target Price | $20.64 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/5 | SMA50 | -14.37% ($9.68) | Rel Volume | 1.97 | Prev Close | $8.81 |
| Employees | 435 | LT Debt/Eq | - | EPS/Sales Surpr. | 94.55% 19.08% | SMA200 | -3.58% ($8.6) | Avg Volume(3M) | 4.35M | Price | $8.29 |
| IPO | 1994/3/4 | Option/Short | Yes/Yes | Trades | 35859 | Volume | 8,568,351 | Change | -5.85% |
Company
BCRX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A US biopharmaceutical company that develops and commercializes treatments for rare diseases. It has commercialized an oral therapy for the prevention of hereditary angioedema while developing a follow-on pipeline targeting rare and immunological diseases. With a model that combines the expansion of prescriptions for its commercial product and pipeline advancement, the company is establishing its presence in areas of unmet need for rare diseases.
Over the past 1 year, roughly in the middle
26% below its 1-year high.
BCRX has weak earning power
40.89% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -290.9% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +17.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 90.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PBE 0.03%
BBP 0.02%
ABLS 0.01%
XBI 0.01%
LABU 0.01%It ranks #4 in the industry
Based on market cap of $2B.
BCRX $2B PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is BCRX?
BCRX belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of BCRX?
The market cap of BCRX is approximately $2.1B, ranking 2,046 within its sector.
What is the 52-week high and low for BCRX?
BCRX has recorded a 52-week high of $11.22 and a low of $6.00.
